Association of choroid plexus volume with motor symptoms and dopaminergic degeneration in Parkinson's disease

BackgroundThe choroid plexus (CP) is involved in the clearance of harmful metabolites from the brain, as a part of the glymphatic system. This study aimed to investigate the association between CP volume (CPV), nigrostriatal dopaminergic degeneration and motor outcomes in Parkinson's disease (PD). MethodsWe retrospectively searched drug-naive patients with early-stage PD who underwent dopamine transporter (DAT) scanning and MRI. Automatic CP segmentation was performed, and the CPV was calculated. The relationship between CPV, DAT availability and Unified PD Rating Scale Part III (UPDRS-III) scores was assessed using multivariate linear regression. We performed longitudinal analyses to assess motor outcomes according to CPV. ResultsCPV was negatively associated with DAT availability in each striatal subregion (anterior caudate, & beta;=-0.134, p=0.012; posterior caudate, & beta;=-0.162, p=0.002; anterior putamen, & beta;=-0.133, p=0.024; posterior putamen, & beta;=-0.125, p=0.039; ventral putamen, & beta;=-0.125, p=0.035), except for the ventral striatum. CPV was positively associated with the UPDRS-III score even after adjusting for DAT availability in the posterior putamen (& beta;=0.121; p=0.035). A larger CPV was associated with the future development of freezing of gait in the Cox regression model (HR 1.539, p=0.027) and a more rapid increase in dopaminergic medication in the linear mixed model (CPVxtime, p=0.037), but was not associated with the risk of developing levodopa-induced dyskinesia or wearing off. ConclusionThese findings suggest that CPV has the potential to serve as a biomarker for baseline and longitudinal motor disabilities in PD.

Automated summary

This study aimed to investigate the association between choroid plexus volume (CPV), nigrostriatal dopaminergic degeneration, and motor outcomes in Parkinson's disease (PD). The study found that CPV was negatively associated with dopamine transporter availability and motor scores, and was positively associated with the risk of developing freezing of gait and an increase in dopaminergic medication. Therefore, CPV has the potential to serve as a biomarker for baseline and longitudinal motor disabilities in PD.